 This study will collect safety data of GlaxoSmithKline Biologicals human papillomavirus HPV vaccine in healthy females of Chinese origin who are unable to receive all three doses of commercially available HPV vaccine before they are 25 years, and were placebo recipients in the primary study NCT00306241. 